• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Dominari Holdings Inc.

    1/8/26 7:55:26 PM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $DOMH alert in real time by email
    S-8 1 ea0272183-s8_dominari.htm REGISTRATION STATEMENT

    As filed with the Securities and Exchange Commission on January 8, 2026

    Registration No. 333-           

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM S-8

     

    REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

     

    DOMINARI HOLDINGS INC.

    (Exact name of registrant as specified in its charter)

     

    Delaware   52-0849320
    (State or Other Jurisdiction of
    Incorporation or Organization)
     

    (IRS Employer

    Identification No.)

     

    725 5th Avenue, 22nd Floor, New York, NY   10022
    (Address of Principal Executive Offices)   (Zip Code)

     

    Dominari Holdings Inc. 2022 Equity Incentive Plan (f/k/a AIkido Pharma Inc. 2022 Equity Incentive Plan)
    (Full Title of the Plan)

     

    Anthony Hayes

    Chief Executive Officer

    Dominari Holdings Inc.
    725 5th Avenue, 22nd Floor

    New York, NY 10022

    (Name and address of agent for service)

     

    (212) 393-4540

    (Telephone number, including area code, of agent for service)

     

    With copies to:

     

    Robert F. Charron, Esq.

    Ellenoff Grossman & Schole LLP

    1345 Avenue of the Americas, 11th Floor

    New York, NY 10105

    (212) 370-1300

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ☐ Accelerated filer ☐
    Non-accelerated filer ☒ Smaller reporting company ☒
        Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. 

     

     

     

     

    REGISTRATION OF ADDITIONAL SHARES
    AND INCORPORATION OF PREVIOUS REGISTRATION Statement by reference

     

    Pursuant to General Instruction E to Form S-8 under the Securities Act of 1933, as amended (the “Securities Act”), this registration statement on Form S-8 (this “Registration Statement”) is filed by Dominari Holdings Inc., a Delaware corporation (the “Registrant” or the “Company”), to register an additional 13,529,833 shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), reserved for issuance under the Dominari Holdings Inc. 2022 Equity Incentive Plan (f/k/a AIkido Pharma Inc. 2022 Equity Incentive Plan) (the “2022 Plan”), adopted by the Company’s Board of Directors, and approved by the Company’s stockholders at the Company’s Annual Meeting of Stockholders on December 5, 2022. On April 7, 2023, the Company filed a registration statement on Form S-8 (Registration No. 333-271179) (the “2023 Registration Statement”) to register 1,100,000 shares of Common Stock reserved for issuance under the 2022 Plan as originally approved by the Company’s stockholders in December 2022.

     

    On January 1, 2024, as the result of an automatic increase in the number of shares of Common Stock available for issuance under the 2022 Plan, pursuant to the provisions of the 2022 Plan, an additional 769,736 shares of Common Stock became available for issuance under the 2022 Plan, and, on December 23, 2024, the Company filed a registration statement on Form S-8 (Registration No. 333-284014) (the “2024 Registration Statement”) to register the additional 769,736 shares of Common Stock reserved for issuance under the 2022 Plan.

     

    On January 1, 2025, as a result of an automatic increase in the number of shares of Common Stock available for issuance under the 2022 Plan, pursuant to the provisions of the 2022 Plan, an additional 1,229,379 shares of Common Stock became available for issuance under the 2022 Plan, and, on January 21, 2025, the Company filed a registration statement on Form S-8 (Registration No. 333- 284378) (the “2025 Registration Statement”) to register the additional 1,229,379 shares of Common Stock reserved for issuance under the 2022 Plan.

     

    On April 1, 2025, as a result of stockholders voting to approve an amendment to Section 4(a) of the 2022 Plan, an additional 10,000,000 shares of Common Stock became available for issuance under the 2022 Plan.

     

    On December 10, 2025, as a result of stockholders voting to approve an amendment to Section 4(a) of the 2022 Plan, an additional 316,346 shares of Common Stock became available for issuance under the 2022 Plan.

     

    On January 1, 2026, as a result of an automatic increase in the number of shares of Common Stock available for issuance under the 2022 Plan, pursuant to the provisions of the 2022 Plan, an additional 3,213,487 shares of Common Stock became available for issuance under the 2022 Plan.

     

    This Registration Statement is being filed to register the additional 13,529,833 shares of Common Stock that became available for issuance under the 2022 Plan pursuant to the stockholder approvals on April 1, 2025 and December 10, 2025 and the automatic increase under the 2022 Plan on January 1, 2026.

     

    Pursuant to General Instruction E to Form S-8 under the Securities Act, the contents of the 2023 Registration Statement, 2024 Registration Statement and 2025 Registration Statement, including the documents incorporated therein by reference, are hereby incorporated by reference into this Registration Statement to the extent not otherwise amended or superseded by the contents hereof. Additionally, in accordance with the instructional note to Part I of Form S-8 as promulgated by the Securities and Exchange Commission (the “Commission”), the information specified by Part I of the Form S-8 has been omitted from this Registration Statement.

     

    1

     

    PART II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3. Incorporation of Documents by Reference.

     

    The Commission allows us to incorporate by reference the information we file with it, which means that we can disclose important information to you by referring you to another document that we have filed separately with the Commission. You should read the information incorporated by reference herein because it is an important part of this prospectus. We incorporate by reference into this prospectus and the registration statement of which this prospectus is a part the information or documents listed below that we have filed with the Commission:

     

    (a) Our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 (File No. 001-41845), filed with the Commission on April 15, 2025 (the “Annual Report”);

     

    (b) All other reports filed by us with the Commission pursuant of Section 13(a) or 15(d) of the Exchange Act since the end of the fiscal year covered by the Annual Report; and

     

    (c) The description of our shares of Common Stock contained in Exhibit 4.2 to the Annual Report.

     

    All reports and documents filed by the Registrant pursuant to Sections 13(a), 13(c), 14, and 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (other than Current Reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that relate to such items) on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement that indicates that all securities offered have been sold or that deregisters all securities then remaining unsold shall be deemed to be incorporated by reference in this Registration Statement and to be part hereof from the date of filing of such reports and documents. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document which also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

     

    Item 8. Exhibits.

     

    Exhibit No.   Exhibit Description
         
    5.1*   Opinion of Ellenoff Grossman & Schole LLP
         
    10.1   2022 Equity Incentive Plan (included as Annex A to the Company’s Definitive Proxy Statement, filed with the Commission on October 21, 2022)
         
    10.2   Amendment No. 1 to 2022 Equity Incentive Plan (included as Annex A to the Company’s Definitive Proxy Statement, filed with the Commission on March 10, 2025)
         
    10.3   Amendment No. 2 to 2022 Equity Incentive Plan (included as Annex A to the Company’s Definitive Proxy Statement, filed with the Commission on November 10, 2025)
         
    23.1*   Consent of Marcum LLP, an independent public accounting firm
         
    23.2*   Consent of Ellenoff Grossman & Schole LLP (included in Exhibit 5.1)
         
    24.1*   Power of Attorney (included on the signature page of this Registration Statement)
         
    107*   Filing Fee Table

     

    *Filed herewith

     

    II-1

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of New York, State of New York, on January 8, 2026.

     

      DOMINARI HOLDINGS INC.
         
      By: /s/ Anthony Hayes
        Anthony Hayes
        Chief Executive Officer

     

    POWER OF ATTORNEY

     

    We, the undersigned officers and directors of Dominari Holdings Inc., hereby constitute and appoint Anthony Hayes, our true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution in his and in his name, place and stead, and in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8 of Dominari Holdings Inc. and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent, full power and authority to do and perform each and every act and thing requisite or necessary to be done in and about the premises, as full to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent or any of them or his substitute or substitutes may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Form S-8 has been signed by the following persons in the capacities and on the dates indicated below. 

     

    Name   Title   Date
             
    /s/ Anthony Hayes   Chief Executive Officer and Chairman of the Board of Directors   January 8, 2026
    Anthony Hayes   (Principal Executive Officer and Principal Financial and Accounting Officer)    
             
    /s/ Kyle Wool        
    Kyle Wool   President and Director   January 8, 2026
             
    /s/ Gregory James Blattner        
    Gregory James Blattner   Director   January 8, 2026
             
    /s/ Kyle Haug        
    Kyle Haug   Director   January 8, 2026
             
    /s/ Brian Parsley        
    Brian Parsley   Director   January 8, 2026

     

    II-2

     

    Get the next $DOMH alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DOMH

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $DOMH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    COO Devall Christopher Franklin was granted 10,000 shares, increasing direct ownership by 7% to 155,702 units (SEC Form 4)

    4 - Dominari Holdings Inc. (0000012239) (Issuer)

    12/12/25 9:48:09 PM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: CEO Hayes Anthony bought $89,054 worth of shares (23,000 units at $3.87), increasing direct ownership by 1% to 1,750,873 units (SEC Form 4)

    4/A - Dominari Holdings Inc. (0000012239) (Issuer)

    12/10/25 9:22:01 PM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: President Wool Kyle Michael bought $96,798 worth of shares (25,000 units at $3.87), increasing direct ownership by 2% to 1,211,828 units (SEC Form 4)

    4/A - Dominari Holdings Inc. (0000012239) (Issuer)

    12/10/25 9:20:35 PM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DOMH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Dominari Holdings Announces Change of Record Date and Payment Date for $10 Million Cash Dividend

    NEW YORK, Dec. 12, 2025 /PRNewswire/ -- Dominari Holdings Inc. (NASDAQ:DOMH) is pleased to announce that, following its press release issued on December 11, 2025, the board of directors has updated the record date and payment date for the previously announced special cash dividend of approximately $10 million, or approximately $0.44 per share. The dividend is now payable on or about January 26, 2026, to DOMH's common stock shareholders and certain DOMH warrant holders (on an as-exercised basis) of record as of the close of business on January 5, 2026. For additional informatio

    12/12/25 5:45:00 PM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dominari Holdings Announces $10 Million Cash Dividend

    NEW YORK, Dec. 11, 2025 /PRNewswire/ -- Dominari Holdings Inc. (NASDAQ:DOMH) is pleased to announce that its board of directors has authorized a special cash dividend of, in the aggregate, approximately $10 million, or approximately $0.44 per share.  The dividend is payable on or about January 23, 2026, to DOMH's common stock shareholders and certain DOMH warrant holders (on an as-exercised basis) of record as of the close of business on December 31, 2025. For additional information about Dominari Holdings Inc., please visit: https://www.dominariholdings.com/ About Dominari Ho

    12/11/25 7:00:00 AM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dominari Expands Strategic Leadership with Appointment of Ambassador Jamie McCourt to Advisory Board

    Dominari Withdraws $2 Billion Shelf Registration NEW YORK, Dec. 8, 2025 /PRNewswire/ -- Dominari Holdings Inc. (NASDAQ:DOMH) today announced a major enhancement to its strategic leadership with the appointment of Ambassador Jamie McCourt to the Advisory Board of Dominari Securities. Separately, the company has formally withdrawn its previously filed $2 billion shelf registration statement, reflecting confidence in its financial position and growth outlook. Globally recognized diplomat, executive and entrepreneur Ambassador Jamie McCourt Joins Advisory Board Ambassador McCourt

    12/8/25 8:30:00 AM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DOMH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: CEO Hayes Anthony bought $89,054 worth of shares (23,000 units at $3.87), increasing direct ownership by 1% to 1,750,873 units (SEC Form 4)

    4/A - Dominari Holdings Inc. (0000012239) (Issuer)

    12/10/25 9:22:01 PM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: President Wool Kyle Michael bought $96,798 worth of shares (25,000 units at $3.87), increasing direct ownership by 2% to 1,211,828 units (SEC Form 4)

    4/A - Dominari Holdings Inc. (0000012239) (Issuer)

    12/10/25 9:20:35 PM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President Wool Kyle Michael decreased direct ownership by 1% to 2,453,817 units (SEC Form 4)

    4 - Dominari Holdings Inc. (0000012239) (Issuer)

    12/10/25 7:54:17 AM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DOMH
    SEC Filings

    View All

    SEC Form S-8 filed by Dominari Holdings Inc.

    S-8 - Dominari Holdings Inc. (0000012239) (Filer)

    1/8/26 7:55:26 PM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dominari Holdings Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - Dominari Holdings Inc. (0000012239) (Filer)

    12/12/25 5:19:12 PM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form RW filed by Dominari Holdings Inc.

    RW - Dominari Holdings Inc. (0000012239) (Filer)

    11/12/25 8:00:13 AM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DOMH
    Leadership Updates

    Live Leadership Updates

    View All

    Dominari Expands Strategic Leadership with Appointment of Ambassador Jamie McCourt to Advisory Board

    Dominari Withdraws $2 Billion Shelf Registration NEW YORK, Dec. 8, 2025 /PRNewswire/ -- Dominari Holdings Inc. (NASDAQ:DOMH) today announced a major enhancement to its strategic leadership with the appointment of Ambassador Jamie McCourt to the Advisory Board of Dominari Securities. Separately, the company has formally withdrawn its previously filed $2 billion shelf registration statement, reflecting confidence in its financial position and growth outlook. Globally recognized diplomat, executive and entrepreneur Ambassador Jamie McCourt Joins Advisory Board Ambassador McCourt

    12/8/25 8:30:00 AM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dominari Securities Receives Approval as a Limited Underwriting Member of the New York Stock Exchange

    Enables direct participation in underwriting activities conducted through NYSE and NYSEAmerican platforms NEW YORK, Oct. 9, 2025 /PRNewswire/ -- Dominari Holdings Inc. (NASDAQ:DOMH) ("Dominari" or the "Company") today announced that its wholly owned subsidiary, Dominari Securities LLC, has been approved as a Limited Underwriting member of the New York Stock Exchange and NYSE American Equities (the "Exchanges") effective October 8, 2025. This approval marks an important regulatory milestone for Dominari Securities as it continues to expand its capabilities within U.S. capital m

    10/9/25 8:00:00 AM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dominari Securities Appoints Communications and Growth Strategist Brian Parsley to Board

    Accomplished entrepreneur and global speaker to strengthen firm's marketing, investor engagement and strategic communications to help drive growth NEW YORK, Sept. 10, 2025 /PRNewswire/ -- Dominari Holdings Inc. (NASDAQ:DOMH), today announced the appointment of Brian Parsley to its Board of Directors. Parsley, an accomplished entrepreneur, behavioral analyst and internationally recognized speaker, will support the firm's growth by enhancing its marketing, investor outreach and overall communications strategy. Mr. Parsley has more than 30 years of experience in entrepreneurship,

    9/10/25 8:30:00 AM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DOMH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Dominari Holdings Inc.

    SC 13D/A - Dominari Holdings Inc. (0000012239) (Subject)

    6/13/24 8:56:04 PM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Dominari Holdings Inc.

    SC 13D/A - Dominari Holdings Inc. (0000012239) (Subject)

    6/13/24 4:32:07 PM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DOMH
    Financials

    Live finance-specific insights

    View All

    Dominari Holdings Announces Change of Record Date and Payment Date for $10 Million Cash Dividend

    NEW YORK, Dec. 12, 2025 /PRNewswire/ -- Dominari Holdings Inc. (NASDAQ:DOMH) is pleased to announce that, following its press release issued on December 11, 2025, the board of directors has updated the record date and payment date for the previously announced special cash dividend of approximately $10 million, or approximately $0.44 per share. The dividend is now payable on or about January 26, 2026, to DOMH's common stock shareholders and certain DOMH warrant holders (on an as-exercised basis) of record as of the close of business on January 5, 2026. For additional informatio

    12/12/25 5:45:00 PM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dominari Holdings Announces $10 Million Cash Dividend

    NEW YORK, Dec. 11, 2025 /PRNewswire/ -- Dominari Holdings Inc. (NASDAQ:DOMH) is pleased to announce that its board of directors has authorized a special cash dividend of, in the aggregate, approximately $10 million, or approximately $0.44 per share.  The dividend is payable on or about January 23, 2026, to DOMH's common stock shareholders and certain DOMH warrant holders (on an as-exercised basis) of record as of the close of business on December 31, 2025. For additional information about Dominari Holdings Inc., please visit: https://www.dominariholdings.com/ About Dominari Ho

    12/11/25 7:00:00 AM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dominari 2025 Revenue Surges 703% in First Nine Months, Balance Sheet Strengthens Significantly

    Q3 Revenue of $50.8 Million, up 49% from Q2, 2025 NEW YORK, Nov. 11, 2025 /PRNewswire/ -- Dominari Holdings Inc. (NASDAQ:DOMH) ("Dominari" or the "Company"), today announced highlights of its financial results for the quarter ended September 30, 2025, which were filed today with the Securities and Exchange Commission ("SEC") in the Company's quarterly SEC Form 10Q. "We achieved remarkable year-to-date revenue growth in the third quarter of more than 700% year-over-year, reflecting strong underwriting activity, robust client engagement and disciplined operational execution," sa

    11/11/25 8:00:00 AM ET
    $ABTC
    $DOMH
    EDP Services
    Technology
    Biotechnology: Pharmaceutical Preparations
    Health Care